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Edited by Judit Ova´diAbstract Clostridium diﬃcile Toxin B (TcdB) glucosylates low
molecular weight GTP-binding proteins of the Rho subfamily
and thereby causes actin re-organization (cell rounding). This
‘‘cytopathic eﬀect’’ has been generally attributed to RhoA inac-
tivation. Here we show that cells expressing non-glucosylatable
Rac1-Q61L are protected from the cytopathic eﬀect of TcdB.
In contrast, cells expressing RhoA-Q63L or mock-transfected
cells are fully susceptible for the cytopathic eﬀect of TcdB. These
ﬁndings are extended to the Rac1/RhoG mimic IpgB1 and the
RhoA mimic IpgB2 from Shigella. Ectopic expression of IpgB1,
but not IpgB2, counteracts the cytopathic eﬀect of TcdB. These
data strongly suggest that Rac1 rather than RhoA glucosylation
is critical for the cytopathic eﬀect of TcdB.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Fibroblast1. Introduction
Cytoskeletal reorganization is important in many cellular re-
sponses, including establishment and maintenance of cell
shape, adhesion, spreading, and motility. Low molecular
weight GTP-binding proteins of the Rho subfamily are critical
regulators of cytoskeletal changes. RhoA regulates the forma-
tion of actin stress ﬁbres, Rac1 regulates the formation of
lamellipodia protrusions and membrane ruﬄes, and Cdc42
triggers ﬁlopodial extensions at the cell periphery [1].
Rho proteins are inactivated by bacterial pathogenicity fac-
tors including the Clostridial glucosylating toxins and the C3-
like ADP-ribosyltransferases [2,3]. Exoenzyme C3 from C. bot-Abbreviations: C3-bot, exoenzyme C3 from Clostridium botulinum; C3-
lim, exoenzyme C3 from Clostridium limosum; Mab, monoclonal
antibody; TcdA, Toxin A from Clostridium diﬃcile strain VPI10643;
TcdB, Toxin B from Clostridium diﬃcile strain VPI10643; TcdBF,
Toxin B from the variant Clostridium diﬃcile serotype F strain 1470;
TcsH, hemorrhagic toxin from Clostridium sordellii; TcsL, lethal toxin
from Clostridium sordellii
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doi:10.1016/j.febslet.2008.10.003ulinum (C3-bot) is the prototype of mono-ADP-ribosyltransfe-
rases that inactivates RhoA/B/C by ADP-ribosylation at Asn-
41 [4]. This covalent modiﬁcation does not impair Rho-eﬀector
coupling but increases the stability of the RhoA-GDI-1 com-
plex, entrapping RhoA in its inactive, GDP-bound state [5–
7]. Inactivation of RhoA by C3-like ADP-ribosyltransferases
causes the disappearance of actin stress ﬁbres and ﬁnally cell
rounding (‘‘cytopathic eﬀect’’) [8–10].
The family of Clostridial glucosylating toxins encompasses
Toxin A (TcdA) and Toxin B (TcdB) from C. diﬃcile as well
as Lethal Toxin (TcsL) and hemorrhagic toxin (TcsH) from
C. sordellii [11]. TcdA and TcdB from the ‘‘reference’’ C. diﬃ-
cile strain VPI10463, which both glucosylate Rho(A,B,C),
Rac1, and Cdc42, are the causative agents of the C. diﬃcile-
associated diarrhea (CDAD) [12]. Glucosylation of Rho pro-
teins causes their functional inactivation due to impaired cou-
pling to their eﬀector and regulatory proteins [7,13]. Treatment
of cultured cell lines with either clostridial glucosylating toxin
causes the disappearance of actin stress ﬁbres, membrane ruf-
ﬂes, and ﬁlopodial extensions, and disrupts focal adhesion
sites. It ﬁnally results in cell rounding (‘‘cytopathic eﬀect’’).
The cytopathic eﬀect of the C. diﬃcile toxins TcdA and TcdB
correlates with the loss of epithelial barrier function of cul-
tured epithelial cells, an established in vitro model for the
CDAD [14]. The term ‘‘cytopathic eﬀect’’ is suitable to distin-
guish cell rounding induced by the inactivation of Rho pro-
teins from cell rounding as a result of cell death (‘‘cytotoxic
eﬀect’’) [15].
The cytopathic eﬀect of TcdB has been attributed to RhoA
inactivation [16]. This paradigm has been challenged by the
observation that the isomeric Toxin B from the ‘‘variant’’ C.
diﬃcile serotype F strain 1470 (TcdBF) that glucosylates
Rac1 but not RhoA, induces the cytopathic eﬀect as well
[12,17]. Furthermore, TcsL that glucosylates Rac1 but not
RhoA causes the cytopathic eﬀect as well. Boquet & Lemichez
proposed that Rac1 rather than RhoA glucosylation is critical
for the cytopathic eﬀect of the glucosylating toxins [18]. To
corroborate this hypothesis, constitutively active (non-glucosy-
latable) Rho proteins as well as the recently described Rho
mimics were applied here to preserve the activity of Rho pro-
teins in TcdB-treated cells [19,20]. We found that cells express-
ing either Rac1-Q61L or the Rac/RhoG mimic IpgB1 were
protected, at least in part, from the cytopathic eﬀect of TcdB.
In contrast, cells expressing either RhoA-Q63L or the RhoA
mimic IpgB2 were as susceptible to the cytopathic eﬀect of
TcdB as mock-transfected cells. These ﬁndings stronglyblished by Elsevier B.V. All rights reserved.
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Fig. 1. The cytopathic eﬀect of TcdB and TcdBF correlates with Rac1
glucosylation. (A) Fibroblasts were treated with either TcdB (3 ng/ml),
TcdBF (100 ng/ml), or cell permeable C3-lim (1 lg/ml) or left
untreated for 4 h. Cell were ﬁxed and the actin cytoskeleton was
stained using rhodamin-phalloidin. The actin cytoskeleton was ana-
lyzed using ﬂuorescence microscopy. (B) Fibroblasts were incubated2. Materials and methods
2.1. Materials
Plasmids encoding for human RhoA-Q63L, Rac1-Q61L, Cdc42-
Q61L (brain isoform), RhoG-G12V, and TC10-Q75L cloned into the
pRK5 Myc vector were kindly provided by Pontus Aspenstroem
[21]. Commercially obtained reagents: UDP-[14C]glucose, [32P]NAD
(Bio Trend), c-Myc-mAb (clone 9E10) (Santa Cruz), Rac1-mAb (clone
102) (Transduction Lab), Rac1-mAb (23A8) (Upstate), beta-actin
mAb (Sigma), horseradish peroxidase conjugated secondary antibody
mouse (Rockland), rhodamine-phalloidin (Sigma–Aldrich).
The glucosylating toxins were from the following strains: TcdB from
C. diﬃcile strain VPI 10463, TcdBF was puriﬁed from C. diﬃcile strain
1470, TcsL from C. sordellii strain 6018 as described [22]. Brieﬂy, the
toxins were precipitated from culture supernatants of the respective
strain by 70% ammonium sulfate saturation. Subsequently, the toxins
were dialyzed and loaded onto MonoQ columns. After dialysis against
buﬀer (50 mM Tris, pH 7.4, 15 mM NaCl), the toxins were ready for
use. C. botulinum exoenzyme C3 (C3-bot), the cell-permeable exoen-
zyme C3 from C. limosum (C3-lim), and all applied Rho proteins, were
produced using the pGEX-2T vector system in Escherichia coli as de-
scribed and puriﬁed using Glu-Sepharose Beads (AP Biotech) [6,23].
2.2. Cell culture
NIH3T3 ﬁbroblasts were cultivated in Dulbeccos medium (Bio-
chrom, +10% FCS, 100 lg/ml penicillin, 100 U/ml streptomycin and
1 mM sodium pyruvate) at 37 C and 5% CO2. For all experiments,
subconﬂuent cells were treated with the toxins for the indicated periods
of time. The cytopathic eﬀect was determined in terms of rounded per
total cells. Subsequently, cells were washed and lysed in a buﬀer con-
taining NaCl (150 mM), Tris (50 mM, pH 7.2), MgCl2 (5 mM), PMSF
(1 mM), and NP40 (1%). After sonication, the post-nuclear fraction
(‘‘lysate’’) was prepared by centrifugation.
2.3. Immunoﬂuorescence
Fibroblasts grown on coverslips were transfected with plasmids
mediating the expression of Myc-tagged Rho proteins using FuGene
Transfection Reagent (Roche) according to the manufacturers instruc-
tions. Cells were ﬁxed with formaldehyde (4%) and permeabilized with
Triton X-100 (0.1%), and immunolabelled using anti-Myc antibodies.
Fluorescence images were recorded using a Zeiss Axiovert M. The eﬃ-
ciency of transfection ranged from 30% to 60%.
2.4. Sequential [32P]-ADP-ribosylation and [14C]glucosylation
Lysates from TcdB-treated or non-treated cells were incubated with
either C. botulinum C3 exoenzyme in the presence of 0.3 lM [32P] NAD
or TcdB in the presence of UDP-[14C]glucose for 30 min at 37 C. The
reaction was terminated by addition of Laemmli sample buﬀer. Subse-
quently, the samples were separated by SDS–PAGE and subjected to
PhosphoImager (Cyclone, Packard) analysis.
2.5. Western blot analysis
Cells were directly lysed in Laemmli sample buﬀer. Proteins were
separated by SDS–PAGE and subsequently transferred onto nitrocel-
lulose membranes. Membranes were blocked with 5% (w/v) non-fat
dried milk in 50 mM Tris, pH 7.2, 150 mM NaCl, 0.05% TWEEN
20 for 60 min; incubation with primary antibody was conducted over
night at 4 C. After treatment of the membrane with secondary anti-
body (1 h), proteins were detected with ECL Femto (Pierce).with increasing concentrations of TcdB for 4 h. Cell lysates were
analyzed either using Rac1-mAb (clone 102), or subjected to [32P]-
ADP-ribosylation, or [14C]-glucosylation. Radioactive signals were
visualized by PhosphorImager analysis. The level of non-glucosylated
Rac1 (d) was quantiﬁed as the ratio of the Rac1 signal obtained with
Rac1-mAb clone 102 and Rac1-mAb clone 23A8. The level of non-
glucosylated RhoA (m) was quantiﬁed as the ratio of [32P]ADP-
ribosylated RhoA from TcdB-treated cells and [32P]ADP-ribosylated
RhoA from non-treated cells. The cytopathic eﬀect (n) was determined
as the ratio of rounded and total cells.2.6. Glucosylation of recombinant Rho proteins
Recombinant GTPases (1 lM) were incubated with the indicated
toxins (20 nM) in glucosylation buﬀer (50 mM Tris, pH 7.2, 150 mM
NaCl, 100 mM KCl, 1 mM MnCl2, 5 mM MgCl2, 100 lg/ml BSA,
10 lM UDP-[14C]glucose, 10 lM UDP-glucose) at 37 C for 30 min.
The reaction was terminated by addition of Laemmli sample buﬀer.
Proteins were separated by SDS–PAGE and analyzed by immunoblot-
ting as above.3. Results
3.1. Correlation of Rac1 glucosylation and the cytopathic eﬀect
Treatment of ﬁbroblasts with Toxin B from C. diﬃcile
(TcdB) caused rounding of NIH3T3 ﬁbroblasts (‘‘cytopathic
eﬀect’’) (Fig. 1A). Toxin B from the ‘‘variant’’ C. diﬃcile sero-
type F strain 1470 (TcdBF) and exoenzyme C3 from C. limo-
sum (C3-lim) that speciﬁcally ADP-ribsoylates RhoA/B/C
I. Halabi-Cabezon et al. / FEBS Letters 582 (2008) 3751–3756 3753caused cell rounding as well (Fig. 1A). C3-lim was applied as a
fusion toxin that exploits the up-take mechanism of the C. bot-
ulinum C2 toxin [23].
Glucosylation of cellular Rho proteins was assessed using
sequential ADP-ribosylation of RhoA/B/C, sequential glu-
cosylation of Rho proteins, and the analysis of Rac1 glucosy-
lation using the glucosylation-sensitive Rac1-mAb(clone 102)Ra
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Fig. 2. Ectopic expression of Rac1-Q61L prevents the cytopathic eﬀect of Tcd
in the presence of UDP-[14C]glucose for 20 min. (B) Fibroblasts were trans
active Rac1, or Cdc42. After 24 h, cells were lysed and active, GTP-bound Ra
by Western-blot analysis using the indicated antibodies. (C) Fibroblasts grow
encoding myc-tagged constitutively active Rac1, RhoA, RhoG, TC10, and
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Fig. 3. Preservation of the cytopathic eﬀect of TcdB by IpgB1. (A)
Fibroblasts grown on coverslips were transiently transfected with
expression constructs encoding EGFP-tagged IpgB1 or IpgB2, respec-
tively. After 24 h, cells were treated with TcdB (0.3 ng/ml) for 3 h, ﬁxed
and permeabilized. Cells were analyzed for expression of EGFP-tagged
IpgB1/IpgB2 and for the actin cytoskeleton using ﬂuorescence
microscopy. (B) The cytopathic eﬀect in cells over-expressing either
EGFP-tagged IpgB1 or IpgB2 was quantiﬁed as the ratio of rounded
and total cells; at least 100 cells were counted for each condition in
three independent experiments.
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showing that the levels of non-glucosylated Rho proteins de-
creased in a TcdB-dependent manner. The level of total
Rac1, however, was unchanged in cells treated with TcdB (de-
tected using Rac1-mAb(23A8), an antibody that recognizes
both glucosylated and non-glucosylated Rac1 (Fig. 1B). This
observation conﬁrmed that the apparent decrease of the
Rac1 staining by Rac1-mAb(102) was due to Rac1 glucosyla-
tion, but not due to Rac1 degradation [15,24]. The level of
beta-actin (as well as that of total Rac1) was not changed upon
TcdB treatment (data not shown). Rho proteins were thus glu-
cosylated in a TcdB concentration-dependent manner. The re-
sults from the three independent methods applied (sequential
ADP-ribosylation, sequential glucosylation, and analysis of
Rac1 glucosylation by the glucosylation-sensitive Rac1-
mAb(102)) resembled each other (Fig. 1B). The cytopathic ef-
fect of TcdB was quantiﬁed in terms of rounded per total cells.
It increased in a TcdB concentration-dependent manner
(Fig. 1B). Thus, glucosylation of either RhoA or Rac1 corre-
lated with an increasing cytopathic eﬀect (Fig. 1B).
3.2. Identiﬁcation of Rho proteins critical for the cytopathic
eﬀect of TcdB
The protein substrate speciﬁcity of TcdB was re-analyzed
exploiting the in vitro glucosyltransferase reaction using re-
combinant Rho proteins. TcdB glucosylated RhoA/B/C,
Rac1, and Cdc42, and the yet non-identiﬁed substrates RhoG
and TC10 (Fig. 2A). TcdBF shared these substrates except for
RhoA/B/C (Fig. 2A). RhoD and RhoE were glucosylated by
neither toxin (Fig. 2A).
Assuming that Rac1 activity is critical for the cytopathic ef-
fect of TcdB, preservation of Rac1 activity in TcdB-treated
cells would be expected to prevent the cytopathic eﬀect of
TcdB. Active, GTP-bound Rho/Ras proteins are protected
from glucosylation by clostridial glucosylating toxins [25,26].
The acceptor amino acid for glucosylation in Rho/Ras proteins
(Thr-37/-35) is involved in the coordination of GTP and there-
fore not accessible for glucosylation [25,26]. To preserve Rac1
activity in TcdB-treated cells, ﬁbroblasts were transfected with
constitutively active Rac1-Q61L. Rac1-Q61L was not glucosy-
lated by TcdB, as assessed by the glucosylation-sensitive Rac1-
mAb(102) (Fig. 2B). Accordingly, the relative state of activity
of Rac1-Q61L (and that of Cdc42-Q61L as well) was compa-
rable in TcdB-treated and non-treated cells (as analyzed using
PAK-CRIB pull-down assay) (Fig. 2B). The cellular levels of
Rac1-Q61L or Cdc42-Q61L (input) were comparable in
TcdB-treated and untreated cells, as analyzed by Western blot-
ting using myc-antibody (Fig. 2B). Rac1-Q61L was thus not
glucosylated in TcdB-treated cells and its expression allowed
the preservation of Rac1 activity in TcdB-treated cells. The le-
vel of endogenous Rac1 (faint band in the mock-transfected
cells) decreased in response to increasing concentrations of
TcdB (analyzed by the glucosylation-sensitive Rac1-
mAb(102)), indicating its glucosylation (Fig. 2B).
Cells were transfected with Rac1-Q61L, RhoA-Q63L,
Cdc42-Q61L, RhoG-G12V, or TC10-Q75L. The expression
of either Rho protein was visualized by immunoﬂuorescence
(Fig. 2C). The cells exhibited stress ﬁbre formation (RhoA-
Q63L) and lamellipodia-like and ﬁlopodia-like structures
(Rac1-Q61L, RhoG-G12V, Cdc42-Q61L, TC10-Q75L) (data
not shown), in line with those ﬁndings previously reported
applying the same constructs [21]. The cells were now analyzedfor their susceptibility to the cytopathic eﬀect of TcdB. Cells
expressing Rac1-Q61L were not susceptible to the cytopathic
eﬀect of TcdB (Fig. 2C and D). In contrast, cells expressing
RhoA-Q63L were as susceptible to the cytopathic eﬀect of
TcdB as mock-transfected cells (Fig. 2C and D). Furthermore,
expression of either Cdc42-Q61L, RhoG-G12V, or TC10-
Q75L partially rescued the cytopathic eﬀect of TcdB, perhaps
due to indirect activation of Rac1 [27,28]. Together, these ﬁnd-
ings strongly support the hypothesis that Rac1 (but not RhoA)
activity is critical for the cytopathic eﬀect of TcdB.
The Shigella eﬀector proteins IpgB1 and IpgB2 have recently
been identiﬁed as mimics of Rac1/RhoG and RhoA, respec-
tively [19,20]. They are suggested to directly bind to and acti-
vate their eﬀector proteins. We employed IpgB1 to preserve
Rac1/RhoG signalling in TcdB-treated cells. Both IpgB1 and
IpgB2 are expected to diﬀer in their three-dimensional struc-
ture from that of Rho proteins [20]. They lack a motif compa-
rable to the eﬀector region of the Rho proteins including the
highly conserved threonine residue that serves as the acceptor
amino acid for glucosylation. Therefore, it is most conceivable
that IpgB1 and IpgB2 are not glucosylated by TcdB. Cells
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ative of Rac1 activation (Fig. 3A). The susceptibility of cells
expressing IpgB1 to the cytopathic eﬀect of TcdB was clearly
reduced compared to cells expressing IpgB2 or GFP alone
(Fig. 3A and B). Thus, these ﬁndings further support the
hypothesis that Rac1 rather than RhoA activity is critical for
the cytopathic eﬀect of TcdB.4. Discussion
Re-analysis of the protein substrate proﬁle of TcdB using re-
combinant proteins reveals that it glucosylates RhoA/B/C,
Rac1, Cdc42, RhoG, and TC10. RhoG and TC10 are yet
non-described substrate proteins of TcdB and TcdBF. Both
RhoG and TC10 are homologous to Rac1 (RhoG:Rac1 = 73%
identity, TC10:Rac1 = 69% identity) [29], making it conceiv-
able that they are glucosylated by the toxins as well. RhoG
was reported to induce lamellipodia formation and membrane
ruﬄing in a Rac1-dependent manner, whereas TC10 induces
the formation of focal adhesion-like structures [27,30]. Due
to its substrate speciﬁcity, TcdB may be classiﬁed as a
‘‘broad-spectrum inhibitor’’ of Rho proteins.
Glucosylation of cellular RhoA and Rac1 was conﬁrmed
using sequential ADP-ribosylation (RhoA) or Western-blot
analysis using the glucosylation-sensitive Rac1-mAb(102),
respectively. We show that the kinetics of either RhoA glu-
cosylation or Rac1 glucosylation correlate with the cytopathic
eﬀect. Cells expressing Rac1-Q61L are not susceptible to the
cytopathic eﬀect of TcdB. In contrast, cells expressing
RhoA-Q63L were as susceptible as mock-transfected cells.
Furthermore, cells expressing the Rac1/RhoG mimic IpgB1
exhibited a reduced susceptibility to the cytopathic eﬀect of
TcdB compared to IpgB2-transfected cells. IpgB1 is suggested
to activate Rac1 through the ELMO/Dock180 signalling cas-
cade [19]. At higher concentrations of TcdB or prolonged toxin
treatment, however, the protective eﬀect of IpgB1 was over-
come (data not shown). Thus, IpgB1 may exert its activity
by activating endogenous Rac1 [19] rather than by direct bind-
ing to Rac1 eﬀector proteins [20]. As preservation of Rac1
activity by ectopic expression of IpgB1 or Rac1-Q61L de-
creased the cytopathic eﬀect of TcdB, we conclude that Rac1
glucosylation rather than RhoA glucosylation causes it. This
conclusion is strongly supported by the observation that glu-
cosylating toxins such as TcdBF and TcsL, which glucosylates
Rac1 but not RhoA cause the cytopathic eﬀect as well.
Although often applied, the method of over-expression of
Rho proteins may cause some problems in the interpretation
of the results. Over-expression of Rho proteins may not neces-
sarily result in the speciﬁcity previously anticipated [31], e.g.
Rac1-Q61L is shown to activate endogenous RhoG and
Cdc42 as well [32]. We here analyzed the activity of constitu-
tively active Rho proteins in TcdB-treated cell, i.e. on the back-
ground of a broad spectrum of endogenous Rho proteins
almost completely inhibited, excluding the cross-activation of
endogenous Rho proteins by over-expressed constitutively ac-
tive Rho proteins. We observed distinct eﬀects of either over-
expressed Rho protein: Rac1-Q61L was highly eﬀective,
whereas Cdc42-Q61L, RhoG-G12V, and TC10 were partially
eﬀective in protecting the cytopathic eﬀect. RhoA-Q63L was
not capable of preventing the cytopathic eﬀect. These distinct
eﬀects were not concentration eﬀects, as analysis of the levelsof expression by Western blotting using anti-myc antibody
showed that they were fairly comparable, as exemplarily
shown for Rac1-Q61L and Cdc42-Q61L (Fig. 2B).
Expression of either wildtype RhoA, RhoB or RhoC was re-
ported to transiently reduce the susceptibility of Hela cells to
the cytopathic eﬀect of TcdB [33]. In contrast, we observed
here that RhoA-Q63L does not aﬀect the susceptibility of cells
to the cytopathic eﬀect of TcdB. This apparent contradiction
may be based on the fact that ectopically expressed wildtype
RhoA/B/C are glucosylated in TcdB-treated cells [33]. In con-
trast, RhoA-Q63L is not glucosylated in TcdB-treated cells
(this study). Ectopic expression of RhoA/B/C increases the
amount of TcdB substrate proteins, thereby competing with
endogenous Rac1 for glucosylation. This likely results in a
transient protection of endogenous Rac1 from glucosylation.
This conclusion is supported by the ﬁnding that ectopic expres-
sion of wildtype RhoA/B/C does not reduce the susceptibility
of Hela cells of the cytopathic eﬀect of TcsL [33]. RhoA/B/C
are not substrates of TcsL and therefore not capable of com-
peting with endogenous Rac1 for glucosylation.
To provide direct evidence on the biological activity of glu-
cosylated Rac1, one may propose to perform microinjection
experiments [16]. This approach is based on the assumption
that glucosylated Rac1 exhibits a dominant-negative activity
comparable to that of Rac1-T17N. In fact, ectopic expression
of Rac1-T17N causes cell rounding in some cell lines including
Hep2 cells (unpublished observation) but not in NIH3T3 ﬁbro-
blasts or other cell lines [10,34]. For microinjection, Rac1
needs to be glucosylated by TcdB, and then to be separated
from the toxin. We failed, however, to prove that our prepara-
tion of glucosylated Rac1 was indeed free from any traces of
TcdB, precluding this approach.
C3-bot causes a cytopathic eﬀect comparable to that observed
for TcdB [8–10]. Therefore, the cytopathic eﬀect of TcdB has
been attributed to RhoA/B/C glucosylation. This argument is
based on the assumption that C3 speciﬁcally inactivates
RhoA/B/C. Rac1 (i.e. Rho-associated substrate of C3), how-
ever, is ADP-ribosylated by C3-bot as well, at least to some ex-
tent [35–37]. The potential impact of Rac1 inactivation in the
cytopathic eﬀect of C3-bot was previously considered [38]. In
this study, non-ADP-ribosylatable Rac1-N39I-Q61L (not
ADP-ribosylatable Rac1-Q61L) preserved peripheral mem-
brane ruﬄing and focal complex formation in cells treated with
excess amounts of C3-bot [38]. This ﬁnding is consistent with
several reports showing that Rac1 but not RhoA is a critical
player in focal complex formation and membrane ruﬄing [39–
41].
In conclusion, Rac1 rather than RhoA glucosylation ap-
pears to be critical for the cytopathic eﬀect of glucosylating
toxins. Preservation of Rac1 (not of RhoA) activity in colonic
epithelial cells may represent a promising approach for the
treatment of CDAD.Acknowledgements:We thank Ilona Klose for excellent technical assis-
tance. This work was supported by the Deutsche Forschungsgemeins-
chaft (priority programme 1150 Grants GE 1247/1-3 and STR666/2-3).References
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